Characterization of the equine influenza virus H 3 with monoclonal antibodies

1987 ◽  
Vol 94 (3-4) ◽  
pp. 339-346 ◽  
Author(s):  
Judith A. Appleton ◽  
D. F. Antczak ◽  
A. D. Lopes
2014 ◽  
Vol 34 (8) ◽  
pp. 942-948 ◽  
Author(s):  
Mohamed Boukharta ◽  
Nadia Touil ◽  
Elmostafa El Fahim ◽  
Meriame Terta ◽  
Bachir Kissi ◽  
...  

2009 ◽  
Vol 137 (1-2) ◽  
pp. 172-177 ◽  
Author(s):  
Ilse Müller ◽  
Enrique Pinto ◽  
María C. Santibáñez ◽  
María O. Celedón ◽  
Pablo D.T. Valenzuela

2010 ◽  
Vol 144 (3-4) ◽  
pp. 455-460 ◽  
Author(s):  
Ting Qi ◽  
Wei Guo ◽  
Wenqiang Huang ◽  
Lingli Dai ◽  
Liping Zhao ◽  
...  

1998 ◽  
Vol 120 (1) ◽  
pp. 61-70 ◽  
Author(s):  
L. OXBURGH ◽  
L. ÅIKERBLOM ◽  
T. FRIDBERGER ◽  
B. KLINGEBORN ◽  
T. LINNÉ

Four Swedish strains of equine H3N8 influenza virus isolated from outbreaks during the last 4 years were characterized. Antigenic typing using monoclonal antibodies raised against a variety of H3N8 strains showed that the viruses are heterogeneous, the 1993 isolate being closely related to the 1991 Swedish isolate TAB/91 and the other three isolates from 1994 and 1996 being more closely related to each other. This pattern is reflected in the phylogenetic data calculated from nucleotide sequencing of the haemagglutinin genes. H3N8 equine influenza can be seen to be evolving in two distinct lineages, one European and one American. The 1993 isolate is closely related to the European lineage and is the most recent Swedish strain of this lineage to be isolated. The 1994 and 1996 isolates fit into the American lineage, which contains recent isolates from the United States and also Britain. These results indicate that American-type H3N8 viruses have become endemic in Sweden and, in light of the antigenic differences which can be observed between viruses belonging to the two lineages, we believe that equine influenza virus vaccines should be updated with an American-type virus strain.


2014 ◽  
Vol 62 (6) ◽  
pp. 623-631 ◽  
Author(s):  
F. Laabassi ◽  
F. Lecouturier ◽  
G. Amelot ◽  
D. Gaudaire ◽  
B. Mamache ◽  
...  

2019 ◽  
Vol 66 (5) ◽  
pp. 1884-1893 ◽  
Author(s):  
Xinyu Toh ◽  
Moi Lien Soh ◽  
Mee Keun Ng ◽  
Shew Choo Yap ◽  
Nurshilla Harith ◽  
...  

2013 ◽  
Vol 16 (4) ◽  
pp. 663-669
Author(s):  
W. Rozek ◽  
M. Kwasnik ◽  
J.F. Zmudzinski

AbstractChanges in the level of cellular proteins in cells inoculated with equine influenza virus H7N7 and H3N8 were studied with microarray technique. H3N8 induced pro-apoptotic proteins while H7N7 induced both pro- as well as anti-apoptotic factors. The higher level of some cytoskeleton components and proteins involved in the protein quality control was recorded. Relatively high number of proteins involved in the regulation of transcription was down-regulated. The pattern of changes observed for H7N7 and H3N8 may reflect differences in the biological properties of both serotypes.


Vaccines ◽  
2020 ◽  
Vol 8 (4) ◽  
pp. 784
Author(s):  
Sylvia Reemers ◽  
Sander van Bommel ◽  
Qi Cao ◽  
David Sutton ◽  
Saskia van de Zande

Equine influenza virus (EIV) is a major cause of respiratory disease in horses. Vaccination is an effective tool for infection control. Although various EIV vaccines are widely available, major outbreaks occurred in Europe in 2018 involving a new EIV H3N8 FC1 strain. In France, it was reported that both unvaccinated and vaccinated horses were affected despite >80% vaccination coverage and most horses being vaccinated with a vaccine expressing FC1 antigen. This study assessed whether vaccine type, next to antigenic difference between vaccine and field strain, plays a role. Horses were vaccinated with an ISCOMatrix-adjuvanted, whole inactivated virus vaccine (Equilis Prequenza) and experimentally infected with the new FC1 outbreak strain. Serology (HI), clinical signs, and virus shedding were evaluated in vaccinated compared to unvaccinated horses. Results showed a significant reduction in clinical signs and a lack of virus shedding in vaccinated horses compared to unvaccinated controls. From these results, it can be concluded that Equilis Prequenza provides a high level of protection to challenge with the new FC1 outbreak strain. This suggests that, apart from antigenic differences between vaccine and field strain, other aspects of the vaccine may also play an important role in determining field efficacy.


Sign in / Sign up

Export Citation Format

Share Document